AI Consensus Investment Thesis
CRISPR Therapeutics (CRSP) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Buy & Hold
Multiple horizons support ownership with measured follow-through.
1-Year
BUY$62
+15.0%5-Year
BUY$139
+157.0%Latest flagship insight
How a Hidden Pipeline Shift Could Redefine the Future of Genomic Medicine
High consensus across reports indicates that while near-term commercialization of ex-vivo therapies faces severe logistical bottlenecks, the long-term investment thesis hinges on the clinical validation of a highly scalable, wholly-owned in-vivo pipeline. A fortress balance sheet provides critical insulation against restrictive global macroeconomic rate headwinds.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The overarching base-case narrative projects a structural transition from high-friction, low-throughput ex-vivo cellular therapies to highly scalable, high-margin in-vivo genomic platforms. While near-term performance is constrained by restrictive monetary policy, elevated discount rates, and slow commercial adoption of early-stage assets, the company's unassailable liquidity buffer provides absolute insulation against capital market closure. This financial fortressfinancial fortressA strong balance sheet with low debt and high liquidity, providing resilience against economic downturns.View full glossary entry allows organic pipeline progression through the cycle trough, positioning the asset for a powerful long-term re-rating as clinical data matures.
Key insights
- The transition to in-vivo lipid nanoparticle delivery represents a massive expansion in addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry, shifting the business model from rare diseases to broad-population chronic indications.
- A fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry with substantial cash reserves eliminates near-term refinancing risks and prevents dilutive capital raisesdilutive capital raisesIssuing new shares to raise funds, which reduces the ownership percentage of existing shareholders.View full glossary entry during restrictive credit cycles.
- Near-term commercialization of ex-vivo therapies remains bottlenecked by complex manufacturing, patient conditioning logistics, and slow treatment center activation.
- Geopolitical supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry decoupling and regulatory frameworks like the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry favor Western-domiciled intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry and domestic manufacturing assets.
- Next-generation base and prime editing platforms present a durable competitive threat, demanding constant R&D reinvestment to avoid technological obsolescencetechnological obsolescenceThe risk that a product, asset, or capability loses economic usefulness because superior technology emerges.View full glossary entry.
- High discount rates under the hawkish monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry will continue to compress the present value of long-duration cash flows, capping near-term multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The crowd and mainstream financial media view the asset with deep skepticism, framing it as a disappointed, slow-growth story tied entirely to the commercial execution of its first approved ex-vivo therapy. Analysts are highly focused on short-term metrics, such as quarterly patient infusions and authorized treatment center activations, while treating the broader pipeline as a speculative, distant science project. The prevailing market narrative assumes that the complex logistics and grueling patient journey of personalized cell therapies will permanently cap revenue potential. Consequently, the crowd heavily discounts the platform's long-term optionality, viewing the massive cash reserves merely as a buffer against high R&D burn rather than a strategic weapon.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in a fundamental duration mismatch and a misunderstanding of the platform's structural evolution. While the crowd obsessively focuses on the slow, near-term commercial ramp of ex-vivo therapies, they systematically ignore the non-linear potential of the in-vivo pipeline. Ex-vivo treatments are highly complex, low-throughput medical procedures, whereas in-vivo delivery via lipid nanoparticles functions as a highly scalable, high-margin biological software update. Furthermore, the market misprices the company's massive cash reserves as a liability under a high-rate regime, failing to recognize that this fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry provides absolute immunity to capital scarcity, allowing the firm to fully fund its transition to an in-vivo platform without dilutive financing. This creates an asymmetric margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry near the cash-adjusted floor.
Repricing Catalyst
What could make the market recognize and close that gap? The alpha gapalpha gapA difference between an investment view of potential excess return and the excess return implied by current market expectations.View full glossary entry is expected to close forcefully upon the release of definitive Phase 2 clinical data demonstrating durable efficacy and safety for the wholly-owned in-vivo pipeline, particularly in cardiovascular or oncology indications. This clinical milestone, anticipated within the next 12 to 24 months, will physically prove the scalability of systemic delivery without the logistical bottlenecks of ex-vivo cell harvesting. Additionally, successive quarters of accelerating royalty cash flows and strategic platform licensing deals will confirm the transition to a self-sustaining platform, forcing the market to abandon the slow-launch narrative.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
While there is strong consensus that the expected volatility regime remains high and erratic, views diverge on the exact position in the convergence cycle. Some perspectives suggest the asset is in a capitulation or reversal phase due to near-term commercial skepticism, while others argue it is in early discovery or stabilization as the market begins to recognize the long-term potential of the in-vivo pipeline.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop presents a mixed but ultimately defensive setup. The restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry, characterized by higher-for-longer interest rates and steepening yield curves, acts as a severe mechanical headwind that compresses the valuation multiples of long-duration, pre-profit assets. However, the company's fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry, holding nearly two billion dollars in cash with virtually zero debt, serves as an impenetrable shield. This allows the firm to weather the credit contraction better than its undercapitalized peers while earning elevated interest income. Concurrently, geopolitical supply-chain decoupling and biosecurity regulations act as a localized tailwind for Western-domiciled intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on the commercial horizon and risk weighting of the ex-vivo launch versus the in-vivo pipeline. Some perspectives adopt a near-term, forensic focus, emphasizing the immediate cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and the loss-sharing nature of the joint venture. Conversely, other views prioritize a longer-term horizon, assuming that the slow ex-vivo rollout is merely a temporary logistical bottleneck and that the true terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry resides in the highly scalable in-vivo platform. There is also minor disagreement regarding whether recent convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry issuance represents a defensive buffer or an offensive strategic weapon.
Base-Case Forces
Event Risk ScoreHigh69/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| In-Vivo Pipeline Validation | Innovation And Product | +65% | +80% | The transition from ex-vivo cellular manipulation to in-vivo systemic delivery represents the defining phase transitionphase transitionPhase transition describes a nonlinear shift in system behavior when gradual changes cross a threshold and produce a new state.View full glossary entry for the platform. By utilizing lipid nanoparticles to edit genes directly inside the body, the company bypasses the complex, low-throughput logistical bottlenecks of cell harvesting and patient pre-conditioning. Successful clinical readouts for cardiovascular and oncology programs will fundamentally expand the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry from rare diseases to broad-population chronic indications, driving a structural re-rating of the core asset's terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry Supremacy | Capital Allocation | +30% | +10% | The company's unassailable liquidity buffer, featuring nearly two billion dollars in cash and marketable securities with virtually zero debt, provides absolute financial independence. In a restrictive monetary environment where capital costs are high, this fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry eliminates refinancing risks and prevents dilutive capital raisesdilutive capital raisesIssuing new shares to raise funds, which reduces the ownership percentage of existing shareholders.View full glossary entry. This allows management to fund long-duration clinical trials organically, transforming a macro headwind into a competitive advantage as undercapitalized peers face capital starvation. |
| CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry Commercial Scaling and Royalties | Operational Efficiency | +25% | +45% | The commercialization of the first approved gene-editing therapy provides essential validation of the underlying technology platform. While the initial rollout is slow, the gradual activation of global treatment centers and established reimbursement frameworks will drive a predictable, high-margin royalty stream. Because the commercial partner shoulders the majority of marketing and manufacturing costs, these royalties will function as a non-dilutive cash flow to fund the broader pipeline. |
| BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry and Geopolitical Moat | Regulatory | +15% | +10% | Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry and the implementation of the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry structurally restrict Western pharmaceutical reliance on foreign contract manufacturing organizations. The company's vertically integrated domestic manufacturing footprint transforms from a capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry burden into a highly secure, legally protected geopolitical moat. This regulatory tailwind mechanically redirects strategic partnerships and institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry toward compliant Western-domiciled platforms, reducing competitive threats. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Restrictive Discount Ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry Regime | Macroeconomic And Macrofinancial | -30% | -5.0% | The hawkish monetary policy and higher-for-longer interest rate environment act as a severe mechanical headwind for long-duration assets. Because the vast majority of the company's projected free cash flowsfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry reside years in the future, structurally higher discount rates compress the present value of distant clinical milestones. This macroeconomic gravity continuously dampens valuation multiples, decoupling the stock price from near-term operational and scientific progress. |
| Ex-Vivo Manufacturing and Logistical Bottlenecks | Operational Efficiency | -20% | -30% | The commercial scaling of ex-vivo therapies is severely constrained by the physical and operational complexity of the patient journey. The requirement for patient cell extraction, specialized laboratory editing, and grueling pre-conditioning chemotherapy imposes a hard ceiling on throughput. This structural friction ensures that commercial revenues scale linearly rather than exponentially, dragging on near-term cash flows and testing investor patience. |
| Next-Generation Editing Competition | Competitive Positioning | -15% | -15% | The rapid advancement of base editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry, prime editing, and epigenetic modulation platforms represents a durable threat of technological obsolescencetechnological obsolescenceThe risk that a product, asset, or capability loses economic usefulness because superior technology emerges.View full glossary entry. If competitors demonstrate superior precision and safety profiles with fewer off-target effects, the terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry of the company's foundational intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry could be impaired. This competitive pressure forces continuous, capital-intensive R&D reinvestment to maintain market leadership. |
| Sovereign Drug Pricing Pressure | Regulatory | -12% | -15% | Populist political initiatives and strained sovereign healthcare budgets present a challenging pricing environment for multimillion-dollar curative therapies. Government and private payers are increasingly demanding outcome-based reimbursement models or outright price concessions. This regulatory pressure threatens to enforce soft caps on gene therapies, compressing terminal profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry and challenging the assumption of frictionless monopoly pricing powermonopoly pricing powerThe ability to sustain prices above competitive levels because effective competition is limited.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Severe In-Vivo Off-Target Toxicity Event | 20% | -60% | Innovation And Product | A single confirmed case of a severe off-target genomic mutation or systemic toxicity in an in-vivo clinical trial would trigger immediate regulatory clinical holds. This would shatter the platform valuation premise, halting the transition to scalable therapies and isolating the company's valuation entirely to its slow-ramping, margin-compressed ex-vivo assets. |
| Commercial Failure and Cash Runway Exhaustion | 30% | -40% | Operational Efficiency | If the commercial rollout of ex-vivo therapies permanently stalls due to treatment-center bottlenecks or patient refusal of toxic conditioning, anticipated royalty cash flows will fail to materialize. The company would continue to burn cash rapidly, eventually forcing highly dilutive equity raisesdilutive equity raisesIssuing new shares to fund operations, which reduces the ownership percentage of existing shareholders.View full glossary entry in an unforgiving, high-interest-rate macroeconomic environment. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| In-Vivo Cardiovascular Blockbuster Validation | 35% | +65% | Innovation And Product | A successful pivotal readout demonstrating permanent, safe lipid reduction in humans via in-vivo delivery would disrupt the massive cardiovascular chronic disease market. This would instantly transform the company from a niche rare-disease player into a mass-market pharmaceutical giant, triggering an immediate, massive upward re-ratingupward re ratingAn increase in the valuation multiple assigned to a business or asset after market expectations improve.View full glossary entry of terminal cash flows. |
| Outright Megacap Pharmaceutical Acquisition | 25% | +60% | Capital Allocation | As major pharmaceutical companies face impending patent cliffs, the strategic desperation for validated genomic platforms will peak. Given the company's compressed valuation and unassailable balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry, a cash-rich, growth-starved giant could launch a premium-priced acquisition offer to own the foundational gene-editing platform outright, instantly closing the alpha gapalpha gapA difference between an investment view of potential excess return and the excess return implied by current market expectations.View full glossary entry. |
Company Financial Analysis
CRISPR Therapeutics Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company is currently in a classic transition phase from a research-focused business to a commercial one, which makes its current financial numbers look highly unusual. Recent reports show a major drop in revenue and large operating losses because early milestone payments have faded while its first approved drug is just starting to roll out. There is strong agreement that near-term earnings will remain deeply negative due to high research spending and the complex costs of launching a new therapy. However, opinions differ on how quickly this will turn around. Some expect a slow, painful path to profitability because of high shared expenses with its commercial partner, while others believe that once the drug scales up, high-margin royalties will quickly shrink these losses. Ultimately, the company's massive cash reserves ensure it can survive this heavy spending phase without financial distress.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 3.5M | USD -581.6M | USD -345.9M |
| 2024 | USD 35M | USD -366.3M | USD -144.7M |
| 2023 | USD 370M | USD -153.6M | USD -269.8M |
| 2022 | USD 436K | USD -650.2M | USD -532.9M |
| 2021 | USD 913.1M | USD 377.7M | USD 457.3M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | 15.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Currently, the company's profit margins are deeply negative and mathematically distorted because it is spending heavily on research while generating very little initial revenue. There is a clear clash in how analysts view the future margin outlook. Some warn that the high logistical costs of personalized cell therapies will keep profit margins thin for several years, especially under shared-profit agreements. Others argue that once the company transitions to direct-to-patient therapies, the profit margins will behave like software, where every new sale is almost pure profit because the core technology has already been developed. The critical signal to watch is whether the company can successfully launch a direct-to-patient therapy, which would bypass the expensive hospital logistics and unlock massive, long-term profitability.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -568.3M | -16191.4% | -16569.8% |
| 2024 | USD -466.6M | -1333.0% | -1046.4% |
| 2023 | USD -222.5M | -60.1% | -41.5% |
| 2022 | USD -673.2M | -154394.7% | -149122.7% |
| 2021 | USD 373.5M | 40.9% | 41.4% |
Balance sheet and leverage
There is absolute consensus that the company's balance sheet is an unassailable financial fortress. With nearly two billion dollars in cash and short-term investments and virtually zero debt, the company is completely insulated from high interest rates and tight credit markets. This exceptional financial safety provides a comfortable four-to-six-year runway to fund expensive clinical trials without needing to borrow money or issue new shares that would dilute existing investors. While some reports view the recent issuance of convertible debt as a minor warning sign that organic cash flows are still years away, all agree that this massive cash pile is the company's greatest defense. It gives management the rare freedom to focus on long-term scientific breakthroughs without worrying about short-term market panic or bankruptcy risks.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 394.9M | USD 2B | USD 39.7M net debt | 13.32x |
| 2024 | USD 223.7M | USD 1.9B | USD 74.6M net cash | 22.07x |
| 2023 | USD 238.6M | USD 1.7B | USD 150.8M net cash | 17.54x |
| 2022 | USD 244M | USD 1.8B | USD 32.1M net debt | 15.30x |
| 2021 | USD 225M | USD 2.4B | USD 698M net cash | 20.17x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company's heavy spending is not going toward traditional physical assets like factories, but is instead heavily focused on research and development to build its future pipeline. There is high consensus that this massive investment is necessary to transition from complex, personalized treatments to simpler, direct-to-patient therapies. Some reports highlight that the company has also invested defensively in local manufacturing facilities in the United States, which creates a strong protective moat against foreign competitors and supply chain disruptions. While this aggressive spending temporarily drains cash and pressures near-term profits, it is viewed as an offensive move to secure market leadership. Analysts agree that investors must closely monitor clinical trial progress to ensure this heavy spending is successfully creating valuable, patent-protected treatments rather than simply burning through cash.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 914K | USD 265.3M |
| 2024 | USD 1.9M | USD 320.7M |
| 2023 | USD 9.5M | USD 387.3M |
| 2022 | USD 37.2M | USD 461.6M |
| 2021 | USD 81.7M | USD 438.6M |
Quarterly Forecast Scenarios
CRISPR Therapeutics Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $55.27 | $58.48 | $62.48 | $736.09 | |
| $51.96 | $59.77 | $66.23 | $724.14 | |
| $49.36 | $60.14 | $69.49 | $713.57 | |
| $47.38 | $62.09 | $70.39 | $723.38 | |
| $48.25 | $63.88 | $74.15 | $716.61 | |
| $45.84 | $67.46 | $85.27 | $738.34 | |
| $44.54 | $70.03 | $95.50 | $746.91 | |
| $42.76 | $74.68 | $103.14 | $771.93 | |
| $44.89 | $75.24 | $97.99 | $782.73 | |
| $46.24 | $82.01 | $115.63 | $807.31 | |
| $45.32 | $86.36 | $138.75 | $822.72 | |
| $47.13 | $92.13 | $159.56 | $846.10 | |
| $48.07 | $95.46 | $153.18 | $852.53 | |
| $46.63 | $102.47 | $191.48 | $882.91 | |
| $48.96 | $104.90 | $210.62 | $900.46 | |
| $50.43 | $113.32 | $235.90 | $922.67 | |
| $52.45 | $119.12 | $247.69 | $935.91 | |
| $51.40 | $126.47 | $267.51 | $952.30 | |
| $54.48 | $130.48 | $283.56 | $976.28 | |
| $56.66 | $138.78 | $311.91 | $1,002 |
Research Provenance
References & Context
This CRISPR Therapeutics consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).